---
title: "Eliquis (apixaban) in nonvalvular atrial fibrillation: Real-world evidence questions"
description: "Real-world evidence questions on Eliquis (apixaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Eliquis vs Xarelto (rivaroxaban): is there real-world evidence in atrial fibrillation? Eliquis vs Xarelto in adults 65 and older: what did real-world data show (Dawwas 2025)? Eliquis vs Xarelto in adults younger than 65: what did FDA Sentinel data show? Is switching from Eliquis to Xarelto linked to more stroke or bleeding (ATHENS)? 4 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/real-world-evidence"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Eliquis (apixaban) in nonvalvular atrial fibrillation: Real-world evidence questions

Manufacturer: Bristol-Myers Squibb Company; Pfizer Inc  
Prescribing information: [Eliquis](https://packageinserts.bms.com/pi/pi_eliquis.pdf)

## Real-world evidence

<a id="eliquis-rwe-overview"></a>

### Eliquis vs Xarelto (rivaroxaban): is there real-world evidence in atrial fibrillation?

> “There are currently no results from clinical trials comparing ELIQUIS to XARELTO<sup>®</sup> (rivaroxaban) for stroke risk reduction in NVAF.<sup>12, 13</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=There%20are%20currently%20no%20results,for%20stroke%20risk%20reduction%20in)

> “RWE should be reviewed in the context of RCT data. All RWE resources below also include data from the ARISTOTLE clinical trial.”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=RWE%20should%20be%20reviewed%20in,from%20the%20ARISTOTLE%20clinical%20trial.)

> “REAL-WORLD
> OBSERVATIONAL STUDIES
>
> Observational in nature and use data from routine clinical practice
> Patients are not randomized
> Can only evaluate association and therefore are unable to determine causality”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=and%20safety%20data%29-,REAL%2DWORLD,are%20unable%20to%20determine%20causality)

> “independently funded, retrospective, observational real-world database analysis evaluating the association of ELIQUIS vs XARELTO<sup>®</sup> (rivaroxaban) with major ischemic or hemorrhagic events in Medicare beneficiaries with NVAF (N=581,451).<sup>9</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=independently%20funded%2C%20retrospective%2C%20observational%20real%2Dworld%20database%20analysis%20evaluating,in%20Medicare%20beneficiaries%20with%20NVAF)

> “An independently funded, retrospective, observational real-world database analysis on the effectiveness and safety of ELIQUIS compared to XARELTO<sup>®</sup> (rivaroxaban) for patients with NVAF in routine practice.<sup>10</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=An%20independently%20funded%2C%20retrospective%2C%20observational%20real%2Dworld%20database%20analysis%20on,patients%20with%20NVAF%20in%20routine)

> “A retrospective, observational real-world database analysis comparing stroke-related readmissions among hospitalized patients with NVAF treated with OACs in the US.<sup>11</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=A%20retrospective%2C%20observational%20real%2Dworld%20database%20analysis%20comparing,treated%20with%20OACs%20in%20the)

> “Other studies (including RCT and RWD analyses) in adult patients comparing ELIQUIS with other DOACs, which may have used different methods, populations, and outcome definitions, have shown different findings.<sup>14-16,18-25</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=Other%20studies%20%28including%20RCT%20and,outcome%20definitions%2C%20have%20shown%20different)

Note: The statement that no clinical trial results compare Eliquis with Xarelto for stroke risk reduction is the manufacturer's, as captured on November 12, 2026.

<a id="eliquis-rwe-dawwas-65-plus"></a>

### Eliquis vs Xarelto in adults 65 and older: what did real-world data show (Dawwas 2025)?

> “An independently funded, retrospective, observational real-world database analysis comparing the effectiveness and safety of ELIQUIS vs XARELTO<sup>®</sup> (rivaroxaban) in patients with NVAF aged 65 years or older.<sup>5</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=An%20independently%20funded%2C%20retrospective%2C%20observational,NVAF%20aged%2065%20years%20or)

> “OBJECTIVE: To compare stroke/SE and GI bleeding/ICH outcomes with select OACs among patients with 
> NVAF with commercial insurance (with and without Medicare supplemental insurance) aged ≥65 years*
> STUDY DESIGN: Real-world, retrospective, observational, new-user cohort analysis<sup>1,2</sup>
> Patients from the MarketScan<sup>®</sup> database covered by commercial  
> or Medicare supplemental insurance, including: 
> • Treatment-naïve adults ≥65 years with a diagnosis of NVAF 
> • ≥12 months continuous healthcare plan enrollment prior to  
>   OAC initiation date
> • Started OAC* between January 1, 2014 and December 31, 2021
> Primary outcomes:
> • Incidence of stroke/SE 
> • Incidence of GI bleeding/ICH
> These outcomes required hospitalization and were 
> identified based on the first listed diagnosis<sup>1,2†</sup> 
> Cohort Description
> Patients who met inclusion criteria were propensity  
> score matched (1:1) to help balance baseline characteristics
> Assessed Outcomes
> ELIQUIS
> (n=31,896)
> XARELTO 
> (n=31,896)”

Source: [ELIQUIS: Explore the Analysis, page 5, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=5)

> “STROKE/SYSTEMIC EMBOLISM 
> HR=0.81 (95% CI: 0.71–0.93)
> GI BLEEDING/ICH
> HR=0.63 (95% CI: 0.57–0.69)”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=11)

> “In this real-world analysis, ELIQUIS was associated with relative risk reductions  
> of 19% for stroke/SE and 37% for GI bleeding/ICH vs XARELTO”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=11)

> “19% RRR* 
> 2.8 ARR*”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=11)

> “37% RRR* 
> 13.2 ARR*”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=11)

> “RRR was calculated as (1-HR)x100. ARR represents the difference between the event rates and is expressed as per 1000 person-years.”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=11)

> “Statistical note: HRs were represented as XARELTO vs ELIQUIS in the original publication and are inverted in the figures on the left as ELIQUIS vs XARELTO.”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=11)

> “The median duration of follow-up was:
>    –219 days for XARELTO patients (IQR, 82–478 days) 
>    –219 days for ELIQUIS patients (IQR, 83–462 days)”

Source: [ELIQUIS: Explore the Analysis, page 9, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=9)

> “Due to the nature of retrospective, observational, cohort studies, no causal relationships can be 
> inferred, and only statistical associations were assessed
> • In contrast to clinical trials, outcomes were defined by using ICD-9-CM and ICD-10-CM diagnosis 
> codes rather than clinical outcome adjudication”

Source: [ELIQUIS: Explore the Analysis, page 10, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=10)

> “In order to reduce the effect of potential selection bias, propensity score matching was 
> conducted; however, residual confounding is possible due to unmeasured confounders or lack of 
> adjustment for time-dependent confounders. Detailed information on potential confounders, 
> such as health behaviors, adherence measures, and over-the-counter medications, was not 
> available.”

Source: [ELIQUIS: Explore the Analysis, page 10, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/ELQ%20HCP%20Dawwas%20Digital%20Leave%20Behind%20(iPDF)_073125.pdf#page=10)

<a id="eliquis-rwe-sentinel-under-65"></a>

### Eliquis vs Xarelto in adults younger than 65: what did FDA Sentinel data show?

> “An independently funded, retrospective, observational real-world database analysis comparing bleeding and stroke risks of ELIQUIS vs XARELTO<sup>®</sup> (rivaroxaban) in patients younger than 65 years with NVAF.<sup>6,7</sup>
>
> Analysis should not be construed as an actual or implied endorsement by the FDA of any of the products discussed.
> <sup>*</sup>FDA Sentinel is a national safety surveillance system for medical products that is primarily composed of aggregated electronic healthcare and administrative claims data.<sup>7</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=An%20independently%20funded%2C%20retrospective%2C%20observational%20real%2Dworld%20database%20analysis%20comparing%20bleeding,electronic%20healthcare%20and%20administrative%20claims)

> “OBJECTIVE: To compare major extracranial bleeding, GI bleeding, intracranial hemorrhage,
> and thromboembolic stroke outcomes in ELIQUIS or XARELTO users with NVAF aged <65 years
> STUDY DESIGN: Real-world, retrospective, observational, new-user cohort analysis<sup>1,2</sup>”

Source: [ELIQUIS: Explore the Analysis, page 5, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Sentinel_Digital_Leave_Behind.pdf#page=5)

> “Patients aged 21–64 years with NVAF 
> • New, standard-dose DOAC prescription* between October 19, 2010  
> and February 28, 2022 
> 153,978 patients met the inclusion/exclusion criteria 
> • Major extracranial bleeding 
> • GI bleeding 
> • Intracranial hemorrhage
> • Thromboembolic stroke
> Cohort Description
> Patients who met inclusion criteria were weighted with inverse probability 
> treatment weighting (IPTW) to help balance baseline characteristics<sup>†</sup>
> Assessed Outcomes<sup>‡</sup>
> ELIQUIS
> (n=96,013)
> XARELTO 
> (n=57,965)”

Source: [ELIQUIS: Explore the Analysis, page 5, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Sentinel_Digital_Leave_Behind.pdf#page=5)

> “Statistical note: HRs were presented as XARELTO vs ELIQUIS in the original report and were inverted in the figures above as ELIQUIS vs XARELTO.”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Sentinel_Digital_Leave_Behind.pdf#page=11)

> “Major Extracranial Bleeding
> HR=0.52 (95% CI: 0.43–0.64)
> GI Bleeding
> HR=0.52 (95% CI: 0.42–0.65)
> Intracranial Hemorrhage
> HR=0.61 (95% CI: 0.37–1.01)”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Sentinel_Digital_Leave_Behind.pdf#page=11)

> “Thromboembolic Stroke
> HR=0.95 (95% CI: 0.69–1.30)”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Sentinel_Digital_Leave_Behind.pdf#page=11)

> “Data presented here are based on a report of an FDA analysis (August 21, 2024), not a final  
> peer-reviewed publication, and do not reflect labeling decisions for any product.”

Source: [ELIQUIS: Explore the Analysis, page 8, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Sentinel_Digital_Leave_Behind.pdf#page=8)

> “Due to the nature of retrospective, observational cohort studies, no causal relationships can be 
> inferred, and only statistical associations were assessed”

Source: [ELIQUIS: Explore the Analysis, page 10, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/Sentinel_Digital_Leave_Behind.pdf#page=10)

<a id="eliquis-rwe-athens-switching"></a>

### Is switching from Eliquis to Xarelto linked to more stroke or bleeding (ATHENS)?

> “A retrospective, observational real-world database analysis evaluating the outcomes of ELIQUIS compared to XARELTO<sup>®</sup> (rivaroxaban) in patients with NVAF.<sup>8</sup>”

Source: [ELIQUIS: Real-World Evidence, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/realworldevidence#:~:text=A%20retrospective%2C%20observational%20real%2Dworld%20database,%28rivaroxaban%29%20in%20patients%20with)

> “Sponsored by Pfizer Inc. and Bristol-Myers Squibb Co.”

Source: [ELIQUIS: Explore the Analysis, page 1, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=1)

> “STUDY DESIGN: Real-world, retrospective, observational cohort analysis.
> Patients from an Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart Database covered by commercial or Medicare 
> healthcare plans, including:
> • Adult patients with diagnosis of AF on or before index anticoagulant start date  
> • ≥6 months of continuous enrollment prior to DOAC initiation date 
> • Started on ELIQUIS during the study identification period, between January 1, 2013 and December 31, 2021
> • 167,868 patients who started on ELIQUIS met the inclusion/exclusion criteria 
>    – 132,676 patients continued with ELIQUIS
>    – 2901 patients switched to XARELTO. Reasons for switching treatment are unknown 
> • Incidence of stroke/SE 
> • Incidence of major bleeding 
> These outcomes required hospitalization and were identified based on first listed diagnosis. 
> Cohort Description
> Propensity Score Matching (1:5)*
> Assessed Outcomes
> ELIQUIS continuers<sup>†</sup>
> (n=14,500)
> ELIQUIS to XARELTO switchers<sup>‡</sup> 
> (n=2900)”

Source: [ELIQUIS: Explore the Analysis, page 9, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=9)

> “Risks of stroke/SE and major bleeding between the switcher and continuer groups were compared 
> using a Cox proportional hazards model”

Source: [ELIQUIS: Explore the Analysis, page 6, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=6)

> “OUTCOMES: STROKE/SYSTEMIC EMBOLISM  
> IN PATIENTS WHO CONTINUED ON ELIQUIS  
> VS THOSE WHO SWITCHED TO XARELTO<sup>1</sup>
> Retrospective, observational analyses are not intended for direct comparison with clinical trials and are  
> designed to evaluate associations among variables; causality cannot be established in observational analyses.<sup>12</sup>
> The definitions of outcomes, follow-up period, and the patient population in ARISTOTLE were different than in  
> this analysis.<sup>1,2</sup> 
> There are currently no results from clinical trials comparing ELIQUIS to XARELTO.<sup>14,15</sup> 
> Stroke/SE
> HR=1.99 (95% CI: 1.38–2.88)”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=11)

> “99% RRI* 
> 0.78 ARI*”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=11)

> “OUTCOMES: MAJOR BLEEDING IN PATIENTS  
> WHO CONTINUED ON ELIQUIS VS THOSE  
> WHO SWITCHED TO XARELTO<sup>1</sup>”

Source: [ELIQUIS: Explore the Analysis, page 13, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=13)

> “Major Bleeding
> HR=1.80 (95% CI: 1.46–2.23)”

Source: [ELIQUIS: Explore the Analysis, page 13, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=13)

> “80% RRI* 
> 2.15 ARI*”

Source: [ELIQUIS: Explore the Analysis, page 13, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=13)

> “Statistical note: RRI was calculated as (HR-1)x100. ARI represents the difference between the event rates and is expressed as per 100 person-years.
> ARI=absolute risk increase; RRI=relative risk increase.”

Source: [ELIQUIS: Explore the Analysis, page 11, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=11)

> “Due to the nature of retrospective, observational cohort studies, no causal relationships can be 
> inferred, and only associations were assessed”

Source: [ELIQUIS: Explore the Analysis, page 7, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=7)

> “Reasons for switching from ELIQUIS to XARELTO or from XARELTO to ELIQUIS were not captured  
> or evaluated”

Source: [ELIQUIS: Explore the Analysis, page 7, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=7)

> “Sample size for the switch group is much smaller than the sample size for continuers”

Source: [ELIQUIS: Explore the Analysis, page 7, captured 2026-11-12](https://www.eliquis.com/assets/buildeasy/us-commercial/eliquis-hcp/en/resources/pdf/008523-17_ELQ_Athens_Digital_LB_v09.pdf#page=7)

Note: The hazard ratios compare patients who switched from Eliquis to Xarelto with patients who continued Eliquis; in the leave-behind charts, switchers had the higher incidence (stroke/SE 1.53 vs 0.75, major bleeding 4.59 vs 2.44 per 100 person-years).

## Related pages
- [Medical information: Eliquis (apixaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/access-and-coverage)
